FG-2216
FG-2216 (IOX3) is a potent and orally active inhibitor of HIF prolyl hydroxylase-2 (PHD2), with an IC50 of 3.9 μM. FG-2216 induces robust erythropoietin and modest fetal hemoglobin in vivo[1][2][3].
Product Specifications
CAS Number
223387-75-5
Product Name Alternative
IOX3; YM311
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
HIF/HIF Prolyl-Hydroxylase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/FG-2216.html
Purity
99.46
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(O)CNC(C1=C(O)C2=C(C(Cl)=N1)C=CC=C2)=O
Molecular Formula
C12H9ClN2O4
Molecular Weight
280.66
Precautions
H302, H315, H319, H335
References & Citations
[1]Hong YR, et al. [ (4-Hydroxyl-benzo[4,5]thieno[3,2-c]pyridine-3-carbonyl) -amino]-acetic acid derivatives; HIF prolyl 4-hydroxylase inhibitors as oral erythropoietin secretagogues. Bioorg Med Chem Lett. 2013 Nov 1;23 (21) :5953-7.|[2]Hsieh MM, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood. 2007 Sep 15;110 (6) :2140-7.|[3]Bernhardt WM, et, al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010 Dec;21 (12) :2151-6.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
AP52625PU-N 400 µL
Ghrelin O acyltransferase (MBOAT4) (Center) Rabbit Polyclonal Antibody
Sign In for Pricing
View Details 
